CM512 vs JNJ-95597528

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: TSLP + IL-13 · full Atopic Dermatitis pipeline

CM512

Developed by Belenos Biosciences under a licence from Keymed Biosciences

Phase 2 in Atopic Dermatitisbispecific antibody
Weak signal

NCT06553209 · Phase 1 · completed

The study randomly assigned participants to active drug or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. However, its only defined goal was tracking adverse events rather than any measure of skin-disease improvement. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2027 · NCT07230483 (registry estimate)

Reported efficacy

Adverse events (Up to 141 days or up to 169 days): All treatment-related adverse events were Grade 1 or 2; no serious adverse events, no withdrawals for adverse events and no deaths. Pharmacokinetics were linear and dose-proportional from 150 to 1200 mg with a long terminal half-life (mean range 58.7 to 73.6 days). CM512 significantly reduced free TSLP and IL-13 and lowered blood eosinophils, IgE and TARC versus placebo.

Result source: NCT06553209

JNJ-95597528

Developed by Johnson & Johnson

Phase 2 in Atopic Dermatitisbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCM512JNJ-95597528
EASI-75—Not reported—Not reported
IGA 0/1 with 2-point improvement—Not reported—Not reported
EASI-90—Not reported—Not reported
EASI, % change—Not reported—Not reported

EASI-75

CM512
—Not reported
JNJ-95597528
—Not reported

IGA 0/1 with 2-point improvement

CM512
—Not reported
JNJ-95597528
—Not reported

EASI-90

CM512
—Not reported
JNJ-95597528
—Not reported

EASI, % change

CM512
—Not reported
JNJ-95597528
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CM512: no structured comparison results are available for Atopic Dermatitis.

JNJ-95597528: no structured comparison results are available for Atopic Dermatitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM512's landscape · JNJ-95597528's landscape